Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence

Published: Oct 21, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and LONDON, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company's MRX-6 treatment for eczema has been selected as one of the "Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information. Celsus management will present the project to a select group of pharmaceutical company executives at Windhover's Therapeutic Area Partnerships meeting in Boston, November 18-20.

Help employers find you! Check out all the jobs and post your resume.

Back to news